Loss of estrogen receptor Beta expression in follicular thyroid carcinoma predicts poor outcome
| Autor: | Jaana Hagström, Johanna Louhimo, Annukka Heikkilä, Ilkka Heiskanen, Johanna Arola, Hanna Mäenpää, Päivi Siironen, Caj Haglund |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Oncology
Adenoma Adult Male medicine.medical_specialty Pathology Endocrinology Diabetes and Metabolism Thyroid Gland Estrogen receptor Thyroid carcinoma 03 medical and health sciences 0302 clinical medicine Endocrinology Breast cancer Internal medicine Follicular phase Adenocarcinoma Follicular medicine Biomarkers Tumor Estrogen Receptor beta Humans Thyroid Neoplasms Estrogen receptor beta 030304 developmental biology Aged Aged 80 and over 0303 health sciences business.industry Thyroid adenoma Thyroid Estrogen Receptor alpha Middle Aged medicine.disease Prognosis 3. Good health Gene Expression Regulation Neoplastic medicine.anatomical_structure 030220 oncology & carcinogenesis Adenocarcinoma Female business |
| Zdroj: | Thyroid : official journal of the American Thyroid Association. 23(4) |
| ISSN: | 1557-9077 |
| Popis: | Well-differentiated follicular thyroid carcinomas (FTCs) usually act indolently, while aggressively acting tumors are difficult to detect early enough. Estrogen receptors (ERs) have prognostic significance in many cancers. Thyroid diseases, including neoplasms, are associated with the female sex. The prognostic significance of ERs in FTCs has not been reported previously.We studied the role of ERα and ERβ in 83 cases of follicular thyroid adenoma (FTA) and 43 FTC cases, including seven cases of poorly differentiated FTC, obtained from the Department of Surgery, Helsinki University Central Hospital between 1990 and 2009. Patient follow-up was conducted until March 2011. Expression of ERα, ERβ, and MIB-1/Ki-67 was investigated by immunohistochemistry and correlated with clinicopathological characteristics, including survival.Two major observations were apparent. First, ERβ expression was significantly higher in FTA than in FTC, and it was a stronger differential diagnostic marker than MIB-1/Ki-67. Second, low ERβ expression correlated with poor survival in FTC. All cancer-specific deaths due to FTC were among low ERβ-score patients.ERβ is a differential marker for malignancy and could thus be used as a preoperative tool. FTC patients with a low ERβ score need more thorough follow-up and may benefit from more aggressive treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|